Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant [0.03%]
奥司他韦在新生儿和婴幼儿体内处置的药理学考虑因素
Susan M Abdel-Rahman,Jason G Newland,Gregory L Kearns
Susan M Abdel-Rahman
Across much of the world, pandemic H1N1 infection has produced a significant healthcare crisis, reflected in significant morbidity and mortality. Statistics reveal that infection-associated deaths among individuals without pre-existing cond...
Mark Anselmo
Mark Anselmo
The treatment of children with asthma has historically relied upon expert opinion using data extrapolated from adult studies. Over the past few years, landmark studies have been completed providing healthcare professionals with evidence on ...
Loretta Sonnier,Drew Barzman
Loretta Sonnier
Acute agitation is a state of behavioral dyscontrol that requires intervention. Medications available in rapid delivery formats are frequently administered to treat acute agitation, either as a chemical restraint or on a voluntary basis. Pr...
Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study [0.03%]
儿童胃肠炎患者昂丹司琼的用药剂量：一项前瞻性队列剂量反应关系研究
Stephen B Freedman,Elizabeth C Powell,Alejandro A Nava-Ocampo et al.
Stephen B Freedman et al.
Background: Ondansetron is increasingly used to prevent emesis in children with acute gastroenteritis; however, the optimal dose is unknown. Objective: ...
Clinical Trial
Paediatric drugs. 2010 Dec 1;12(6):405-10. DOI:10.2165/11537770-000000000-00000 2010
Strategies to prevent cellular rejection in pediatric heart transplant recipients [0.03%]
预防儿童心脏移植受者细胞排斥的策略
Susan W Denfield
Susan W Denfield
Despite more than 40 years' experience in pediatric heart transplantation, cellular rejection remains a significant cause of morbidity and mortality. In this review, strategies and agents to prevent acute cellular rejection are discussed. S...
Lea S Eiland,Melissa O Hunt
Lea S Eiland
Migraine headaches frequently occur in the pediatric population, with a prevalence of 3% in children 2-7 years of age, 4-11% in children 7-11 years of age, and 8-23% in children 11 years of age and older. Migraine without aura is more than ...
Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review [0.03%]
儿童关节炎肿瘤坏死因子抑制剂治疗的循证评价
Susan Shenoi,Carol A Wallace
Susan Shenoi
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disorder of unknown origin that is often treated with a variety of disease-modifying agents. Tumor necrosis factor (TNF) inhibitors are a group of genetically engineered biologic...
Elizabeth Walter-Nicolet,Daniel Annequin,Valerie Biran et al.
Elizabeth Walter-Nicolet et al.
All neonates in the Neonatal Intensive Care Unit (NICU) or during the first days of life undergo painful and stressful procedures. Epidemiologic studies have shown that pain induced by these procedures is not effectively prevented or is ina...
Mireille van Westreenen,Harm A W M Tiddens
Mireille van Westreenen
With more antibiotic resistance and emerging pathogens in cystic fibrosis (CF) patients, the need for new strategies in the lifelong treatment of pulmonary infection has increased. Most of the focus is on chronic infection with Pseudomonas ...
Clinical significance of medication reconciliation in children admitted to a UK pediatric hospital: observational study of neurosurgical patients [0.03%]
一项观察性研究：药物治疗一致性在英国一家儿科医院入院儿童中的临床意义（以神经外科患者为例）
David R P Terry,Guirish A Solanki,Anthony G Sinclair et al.
David R P Terry et al.
Background: In December 2007, the National Institute for Health and Clinical Excellence and the National Patient Safety Agency in the UK (NICE-NPSA) published guidance that recommends all adults admitted to hospital recei...
Clinical Trial
Paediatric drugs. 2010 Oct 1;12(5):331-7. DOI:10.2165/11316230-000000000-00000 2010